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ABSTRACT 
Purpose: The Mammography Quality Standards Act (MQSA) was enacted in 1992 to set national standards for 
high-quality  mammography,  including  standards  for  mammographic  X-ray  equipment,  patient  dose,  clinical  image 
quality, and related technical parameters. The MQSA also requires minimum qualifications for radiologic technologists, 
interpreting physicians and medical physicists, mandates acceptable practices for quality-control, quality-assurance, and 
requires processes to audit medical outcomes. This paper presents the findings of MQSA inspections of facilities, which 
characterize significant factors affecting mammography quality in the United States. 
Materials  and  Methods:  Trained  inspectors  collected  data  regarding  X-ray  technical  factors,  made  exposure 
measurements for the determination of mean glandular dose (MGD), evaluated image quality, and inspected the quality 
of  the  film-processing  environment.  The  average  annual  facility  and  total  U.S.  screening  exam  workloads  were 
computed using workload data reported by facilities. 
Results: Mammography facilities have made technical improvements as evidenced by a narrower distribution of 
doses, higher phantom-film  background optical densities  associated  with higher phantom  image-quality  scores, and 
better film processing. It is estimated that approximately 36 million screening mammography exams were conducted in 
2006, a rate that is almost triple the exam volume estimated for 1997. Digital mammography (DM) is now in use at 
approximately 14% (1,191 of 8,834) of MQSA-certified mammography facilities. The results indicate that DM can offer 
lower  dose  to  the  patient  while  providing  comparable  or  better  image  quality.  © 2007  Biomedical  Imaging  and 
Intervention Journal. All rights reserved. 
 
INTRODUCTION 
The Mammography Quality Standards Act (MQSA) 
of 1992 was enacted to set national standards for high-
quality mammography and ensure that clinical facilities 
in the U.S. meet those standards. In 1995, the Food and 
Drug  Administration  (FDA)  initiated  a  program  of 
inspections  of  the  then  approximately  10,000 
mammography  facilities  to  assess  compliance  with  the 
MQSA standards. Trained inspectors collected exposure 
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and technique data to determine radiation dose, evaluated 
phantom image quality, and  tested the film processing 
environment to ensure that clinical mammograms were 
developed appropriately. The facility’s medical records 
were also evaluated for compliance with quality control 
and  quality  assurance  standards,  appropriate  medical-
audit  processes,  and  for  proper  documentation  of  the 
professional  qualifications  of  interpreting  physicians, 
radiologic  technologists,  and  medical  physicists. 
Facilities that do not meet these standards must respond 
with an acceptable corrective plan or face legal action. 
The  specific  MQSA  technical  standards  for  X-ray 
equipment,  patient  dose,  and  image  quality  were 
motivated in part by studies between the 1970s and the 
early  1990s  [1,2]  that  documented  the  broad  range  of 
technical performance by  mammography  facilities. For 
example, although mammography quality had improved 
substantially as a result of better equipment performance 
through  dedicated  screen  and  film  combinations, 
improved  film  processing,  and  the  use  of  grids,  other 
technical  parameters-  dose,  background  film  optical 
density,  and  image  quality  indicators-  still  showed  a 
broad  range  of  values.  The  American  College  of 
Radiology (ACR) had initiated an accreditation program 
for mammography, and facilities could also be accredited 
through their state or become certified with the Health 
Care  Financing  Administration  (HCFA).  However  in 
1992,  23%  of  mammography  facilities  carried  no 
credentials from a recognised professional organisation 
[2]. A subsequent study by Suleiman [3] et al. in 1999 
documented  improvements  after  three  years  of  MQSA 
inspections for most areas of technical performance. This 
report  discusses  further  trends  in  the  practice  of 
mammography after 11 years of MQSA inspections, and 
it focuses on technical indicators of quality and trends in 
the  rate  at  which  the  U.S.  population  is  screened  for 
breast cancer. 
Prior to the early 2000s mammography in the U.S. 
was  based  essentially  on  screen-film  (SF)  technology. 
Digital  mammography  (DM)  was  first  approved  for 
clinical use in the U.S. in 2000 and is now offered in 
14% of MQSA-certified facilities. It has unique technical 
advantages over conventional screen-film technology by 
separating the technology for capturing images from the 
media  for  viewing  and  storing  them.  A  disadvantage, 
however,  is  that  unlike  film,  whose  inherently  limited 
sensitometric  range  of  exposure  acts  to  constrain  the 
dose  to  the  patient,  DM  equipment  is  capable  of 
producing images of acceptable quality for a broad range 
of  doses  [4].  Nevertheless,  studies  [5,6]  indicate  the 
potential  for  DM  to  offer  a  lower  dose  than  SF 
technology, and the extensive ACR Imaging Network-
Digital  Mammographic  Imaging  Screening  Trial 
(ACRIN-DMIST)  study  comparing  DM  and  SF 
concluded  that  DM  is  clinically  superior  for  patients 
under  the  age  of  50  years,  premenopausal  or 
perimenopausal  patients,  and  patients  with 
radiographically  dense  breasts,  but  is  otherwise 
comparable in overall diagnostic accuracy for screening 
for  breast  cancer  [7].  This  paper  also  compares 
inspection findings for DM with those of conventional 
SF imaging and discusses the impact of DM on general 
practice. 
Finally, although some studies question the benefit 
of  population-wide  mammography  screening  [8],  it  is 
generally accepted that there is benefit to the patient over 
and  above  the  radiation  and  other  risks  involved 
[9,10,11].  This  paper  also  examines  facility  annual 
screening  workloads  and  provides  estimates  for  total 
annual exam volumes in the U.S. 
EQUIPMENT AND PROCEDURES 
Each MQSA-certified inspector is required to pass a 
series of three training courses provided by the FDA and 
complete  additional  field  testing  prior  to  conducting 
MQSA  inspections  independently.  Each  inspector  was 
provided all the necessary equipment to make radiation 
dosimetry  measurements,  evaluate  image  quality  and 
film  processing  quality,  and  inspect  the  processing 
darkroom environment. Exposure measurements for the 
determination of beam quality and mean glandular dose 
(MGD) were made with the MDH model 1015 (Radcal 
Corporation, Monrovia, CA) survey meter equipped with 
the  10X5-6M  mammography  ionisation  chamber.  The 
radiation meter and ionisation chamber were calibrated 
annually by the FDA’s X-ray calibration facility, which 
is  accredited  by  the  National  Voluntary  Laboratory 
Accreditation  Program  (NVLAP).  Exposure 
measurements were done with a standard mammography 
phantom  having  radiographic  attenuation  properties 
equivalent  to  that  of  a  4.2-cm  compressed  breast 
composed  of  50%  glandular  and  50%  adipose  tissue. 
Beam quality (half-value layer) was determined for the 
clinically  configured  kVp  using  type  1145  aluminum. 
MGD in this standard breast model was then computed 
using  conversion  factors  derived  by  Wu,  Barnes  and 
Tucker  [12].  The  phantom  also  contains  three  sets  of 
image-quality  test  objects:  fibril-like  objects,  speck 
groups that simulate micro-calcifications, and mass-like 
objects,  and  it  is  commercially  available  (model  156 
mammography  accreditation  phantom,  Gammex  RMI, 
Inc., Middleton, WI). A radiograph of the phantom was 
acquired using the same technical factors as those used 
for dosimetry data collection, and it was then evaluated 
for  appropriate  background  optical  density  and 
acceptable  image  quality.  MQSA  requirements  for 
phantom  film  image  quality  include  a  minimum 
background optical density of 1.2 and minimum scores 
for  the  three  groups  of  test  objects  (including  artefact 
subtraction): four fibers out of a possible score of six, 
three  speck  groups  out  of  a  possible  five  groups,  and 
three masses out of a possible score of five. If a phantom 
radiograph failed for one or more of the test objects, a 
second radiograph was scored to confirm the assessment 
prior to citing the facility as non-compliant. After May 
2006,  MQSA  inspectors  no  longer  measured 
mammographic  phantom  doses  themselves  but  instead 
captured dose values documented in the reports of the 
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required  annual  medical  physics  surveys.  During  the 
transition away from independent dose measurements by 
MQSA  inspectors,  the  FDA  conducted  a  comparison 
study and validated (p < 0.001) the equivalence of the 
two means of assessing the dose in the standard breast. 
Film  processing  quality  was  evaluated  using  the 
Sensitometric  Technique  for  the  Evaluation  of 
Processing  (STEP)  [3,13].  A  reference  automatic  film 
processor was configured for processing a selected test 
film according to the specifications recommended by the 
film  manufacturer.  The  same  film  type  was  then 
distributed  to  all  MQSA  inspectors  along  with 
sensitometers  calibrated  to  an  FDA  reference 
sensitometer, and densitometers that were calibrated to 
the  National  Institute  of  Standards  and  Technology 
(NIST) reference standard densitometry step tablet (SRM 
1001).  A  relative  speed  value  was  determined  for  the 
facility’s film processor based on a comparison of optical 
densities  from  the  test  film  processed  at  the  facility 
versus  the  same  film  when  processed  in  the  FDA 
reference film processor. A processing speed of 100 was 
assigned  if  the  tested  film  processor  was  operating  in 
close  agreement  with  film  manufacturer  specifications, 
whereas  speeds  greater  than  120  or  less  than  80  (for 
standard cycle processing) indicate substantial deviation 
from  acceptable  film-processing  levels.  A  film 
processing speed below 80 indicates substantial under-
processing of the film and a facility could be motivated 
to compensate by increasing exposure. For this reason, 
MQSA  regulations  require  a  minimum  film  processor 
speed of 80. Extended cycle processing, where the film is 
developed  over  a  longer  period  of  time  (a  total 
development  time  of  approximately  3  minutes  as 
opposed  to  90  seconds  typically  for  standard  cycle), 
results in a STEP processing speed of approximately 130 
or greater depending on the processor and the film brand 
and type. MQSA requires extended cycle film processors 
to have a minimum processing speed of 100. MQSA has 
not  specified  a  maximum  permissible  film  processor 
speed for either processing cycle. 
An  undeveloped  radiograph  of  the  phantom  was 
used to evaluate the darkroom environment for sources 
of radiographic fog. The film was placed in an area of 
the  darkroom  where  mammography  film  is  routinely 
handled, and then it was bisected so that approximately 
half of the latent image of the phantom was exposed to 
ambient  darkroom  conditions  for  2  minutes.  The  film 
was then developed and inspected for an increase in the 
background optical density. If a distinct area of higher 
optical density was observed on the exposed side of the 
border, then the inspector determined the net increase in 
optical  density  across  the  border.  MQSA  requires  that 
facilities  maintain  darkroom  fog  levels  of  net  optical 
density not greater than 0.05. 
MQSA-certified  clinical  facilities  began  reporting 
annual  screening  mammography  workloads  in  1997. 
Facilities were asked to provide annual workload rates 
during  their  initial  application  for  mammography 
accreditation and during subsequent certification renewal. 
Average facility and total U.S. screening workloads were 
then  derived  using  figures  for  the  total  number  of 
certified  mammography  facilities.  It  was  assumed  that 
the workload sample set reported to FDA for each year, 
ranging from 7% to nearly 30% of all certified facilities, 
is representative of the U.S. state of practice. 
RESULTS 
Between  1997  and  2006,  the  total  number  of 
screening  mammography exams performed annually in 
the U.S. increased linearly (r
2=0.91) from approximately 
13.8 ± 1.6 (mean ± standard error) million exams to 35.8 
± 1.9 million exams (Figure 1). Figure 1 also displays the 
contribution  to  the  total  U.S.  screening  workload  for 
specific facility types: hospitals, private practice facilities 
such as outpatient radiology  facilities, dedicated breast 
clinics,  and  facilities  that  were  classified  as  ‘other’  if 
they  did  not  meet  the  criteria  for  the  preceding  three 
facility categories. The calculations do not account for 
additional  contributions  from  a  small  number 
(approximately  30)  of  the  Department  of  Veterans 
Affairs facilities that may perform mammography but are 
not  required  to  be  compliant  with  MQSA  regulations. 
Hospitals and private practices, which from 1995 to 2006 
constituted approximately 42% and 48% of all certified 
mammography  facilities  respectively,  consistently 
contributed the majority (over 80 percent) of screening 
exams. Dedicated breast clinics, which account for less 
than 6% of all mammography facilities, were found to 
consistently have the highest average facility screening 
exam  workload  of  all  identifiable  facility  types 
(excluding  ‘other’)  (Figure  2).  All  types  of  facilities 
increased their number of mammography units (Figure 3), 
which is consistent with the observation that while the 
number of certified mammography facilities has actually 
decreased  since  1995  from  approximately  10,000 
facilities to just over 8,800 facilities, the total number of 
exams in the U.S. has increased substantially. 
Dose and Image Quality 
Tables  1  and  2  summarize  statistics  for  selected 
technical aspects of mammography in the U.S. for 1995 
and  2006.  During  this  time  period  there  was  a 
statistically  significant  increase  in  average  MGD  (p  < 
0.001) from 1.51 mGy to 1.78 mGy (Tables 1 and 2). 
The  distribution  of  doses  (Figure  4)  about  the  mean 
decreased  during  the  same  time  period,  and  this  trend 
was observed across every type of facility. Dose is partly 
determined  by  the  selected  tube  potential  (kVp),  and 
although the mean clinically selected tube voltage (kVp) 
did not change appreciably between 1995 and 2006, the 
distribution has narrowed (Figure 5). Over 90% (7,865 of 
8,586) of inspected mammography units are now using 
either 25 or 26 kV, whereas in 1995 over 25% (3,068 of 
11,697)  of  inspected  units  were  operated  at  27  kV  or 
higher.  The  standard  deviation  for  kVp  decreased  by 
almost half for every type of facility except breast clinics, 
which had the narrowest distribution in 1995. Half-value 
layer (HVL) followed a trend similar to that for kVp. The 
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Figure 1  Total U.S. screening mammography annual examination workload, and contributions by facility type. 
Standard errors for the total annual estimates ranged between 3% and 12%. 
 
 
 
 
 
Figure 2  Box-whisker plots of facility screening mammography workloads reported between January 2006 and 
October 2006. Box bottom and top borders are 25
th and 75
th percentiles respectively, and box contents 
are 50
th percentile (line) and mean value (diamond). Whiskers indicate 5
th and 95
th percentiles. 
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Figure 3  Distributions for 1995 (left) and 2006 (right) of the number of mammography units per facility used for 
mammography examinations by facility type. 
 
 
 
 
 
 
Figure 4  Box-whisker plots of mean glandular dose from MQSA inspections conducted in 1995 and 2006. Dose 
values for 1995 are those determined by the MQSA inspector. Values for 2006 are those reported in the 
facility  medical  physics  survey  report.  Box  bottom  and  top  borders  are  25
th  and  75
th  percentiles 
respectively, and box contents are 50
th percentile (line) and mean value (diamond). Whiskers indicate 5
th 
and 95
th percentiles. 
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Figure 5  Distributions of mammography unit clinically selected tube potential (kVp) for 1995 and 2006 MQSA 
inspections. 
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mean  for  HVL  changed  very  little  across  all  types  of 
facility  since  1995,  but  private  practice  sites  had  a 
standard deviation for HVL in 2006 that was less than 
half of the standard deviation for 1995. 
Although a higher dose translates to higher radiation 
risk  for  the  patient,  MQSA  data  also  demonstrated  an 
increase  in  benefit  as  indicated  by  improved  image 
quality performance. Phantom image background optical 
density  increased  substantially  from  a  mean  optical 
density  of  1.42  in  1995  to  1.85  in  2006. This  finding 
indicates that film contrast performance should improve 
because  most  mammography  films  currently  in  use 
provide  optimal  image  contrast  at  optical  densities 
approaching  2.0  [14].  Indeed,  although  there  was 
improvement in all three object groups (Tables 1 and 2), 
the fibre and mass groups showed the most statistically 
significant  improvement  between  1995  and  2006,  the 
visualisations  of  which  are  dependent  on  the  contrast 
performance  of  the  film  and  therefore  sensitive  to  the 
background  optical  density  [15].  MQSA  requires 
mammography  facilities  to  maintain  a  phantom  image 
background optical density of at least 1.2. 
Artefacts are a detriment to the clinical value of the 
mammogram and can arise from many sources including 
contaminated  film  cassettes,  the  film  processor,  the 
darkroom environment, improper film handling, and the 
mammography  unit  compression  paddle,  among  other 
sources [16]. Between 1995 and 2006, there was a 10% 
increase  in  the  incidence  of  artefacts  reported  on 
phantom image films scored by MQSA inspectors from 
60% (6,979 of 11,676) of inspected mammography units 
in  1995  to  70%  (6,502  of  9,307)  of  inspected 
mammography units. Across all types of facilities, speck-
like  artefacts  were  the  most  frequent  type  reported, 
occurring on 58% (6,745 of 11,676) of mammography 
units inspected in 1995 and on 68% (6,293 of 9,307) of 
mammography  units  inspected  in  2006.  Mass-like 
artefacts were the least frequently reported artefact type, 
and  occurred  on  less  than  5%  of  mammography  units 
1995  (523  of  11,676)  and  2006  (323  of  9,307). 
Improvements  in  film  processing  technology, 
maintenance  of  mammography  equipment,  and 
adherence  to  acceptable  quality  control  and  quality 
assurance  practices  can  reduce  artefacts.  However,  if 
film  contrast  performance  improves  as  indicated  by 
higher  background  optical  densities,  then  the 
visualisation of artefacts may also improve. Finally, the 
training and experience of inspectors can influence the 
reporting of artefacts. 
Film processing and darkroom fog 
Reports have documented substantial improvements 
in  film  processing  quality  by  mammography  facilities 
between  1985  and  1997  [2,3].  During  this  period, 
extended  cycle  processing  was  used  by  a  substantial 
number of facilities. In 1992, 26% of surveyed facilities 
claimed  to  use  extended  cycle  processing,  and  three 
quarters of these sites had sub-optimal processing quality 
for this particular processing cycle [2]. The rate of film 
processors that facilities claimed to operate in extended 
cycle mode reached 43% (2,743 of 6,459) in 1995, but 
by  2006  extended  cycle  processing  nearly  vanished. 
Nearly  97%  (5,861  of  6,068)  of  film  processors  are 
presently  being  operated  in  a  standard  cycle  mode. 
Regardless  of  the  processing  cycle,  MQSA  inspection 
results  document  that  mammography  facilities  have 
maintained high quality in film processing. During the 
first year of inspections 4% (243 of 6,459) of tested film 
processors (all processor cycles) were found to have a 
STEP processing speed below the MQSA action limit, 
and by 2006 this percentage dropped to near zero (3 of 
6,068).  The  high  rate  of  compliance  with  the  MQSA 
standard for film processing can be attributed to better 
quality  control  and  quality  assurance  practices, 
improvements  in  film  and  chemical  processing 
technologies,  and  a  heightened  awareness  by  facilities 
and  the  professional  community  regarding  the  impact 
that film processing quality can have on clinical image 
quality. Whereas film processor control charting merely 
tracks  the  drifting  of  processing  quality  from  a  pre-
established  and  possibly  arbitrary  operating  level,  the 
STEP  film  processor  test  can  provide  a  benchmark 
operating point for film processing of optimal quality. 
Reducing radiographic film fog in the darkroom to 
acceptable levels is a simple yet often ignored aspect of 
quality  control.  In  1992,  62%  of  clinical  facilities  had 
darkroom  fog  levels  in  excess  of  the  current  MQSA 
standard (net optical density no greater than 0.05) [2]. 
During the first year of MQSA inspections, 11% (778 of 
7,030) of inspected darkrooms exceeded this limit, and 
by 2006, the non-compliance rate dropped to less than 
5%  (233  of  5,587),  with  breast  clinics  showing  the 
highest rate of compliance (Table 2). 
Digital mammography 
Table 2 includes findings of selected parameters for 
DM  and  SF  units  inspected  between  January  and 
September 2006. DM was first approved in the U.S. in 
2000, and currently there are approximately 1,689 DM 
units  in  use  at  1,191  certified  mammography  facilities 
(Figure 6), comprising approximately 14% of the total 
population of certified mammography facilities. Figure 7 
shows a  geographical distribution of DM sites and SF 
sites.  Because  of  the  complexities  regarding  the 
evaluation of dose and quality assurance/quality control 
procedures  that  tended  to  be  specific  to  each 
manufacturer,  the  FDA  conducted  abbreviated 
inspections  of  digital  facilities  to  verify  that  the 
manufacturers’  recommended  practices  were  being 
instituted. MGD was captured from the medical physics 
survey report, and image quality was evaluated by the 
FDA inspector using the same standard phantom as that 
used  for  screen-film  mammography.  Data  analysis  of 
DM  was  conducted  on  inspections  that  took  place 
between  August  2005  and  October  2006  in  order  to 
include all inspected digital facilities.  
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Figure 6  Number of accredited digital mammography (DM) units (circles) and the number of certified digital 
mammography facilities (squares). 
 
 
 
 
 
Figure 7  Geographic distribution of screen-film and digital facilities in the U.S. for 2005-2006. A facility was 
classified as a digital site if it had at least one digital mammography unit. A facility that has digital 
mammography may also have conventional screen-film technology, and therefore was included in the 
latter category as well. 
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Workload 
The  distribution  of  digital  equipment  across  the 
different types of facilities is similar to that for screen-
film equipment (Figure 8). The majority of digital sites 
are hospitals; however breast clinics comprise 11% (72 
of 633) of digital sites compared with 6% (345 of 6,010) 
of  screen-film  sites.  Facilities  using  DM  reported  an 
average facility annual workload (6,938 exams per year, 
N=75),  approximately  double  the  average  for  SF  sites 
(3,524 exams per year, N=1212) (Figures 9). 
Dose and Image Quality 
Figures 10 and 11 display distributions of MGD and 
phantom image quality score for facilities using SF and 
DM. The average MGD for DM units (1.63 mGy) was 
statistically lower (p < 0.001) than that for SF units (1.80 
mGy).  Both  means  are  well  below  the  MQSA 
compliance  limit  for  MGD  of  3.0  mGy  for  a  single 
(craniocaudal) view. The standard deviations for MGD 
in  Table  2  and  the  dose  distributions  in  Figure  10 
highlight  the  broader  range  of  doses  for  DM.  MQSA 
inspectors  did  not  collect  any  dose-related  technical 
factors such as clinically selected kVp, beam quality, or 
target-filter selection during the inspection of DM units, 
and  therefore  it  is  not  possible  to  compare  these 
parameters between the two technologies. 
The  MQSA  inspector  imaged  the  phantom  on  the 
DM  unit  and  scored  the  image  using  the  same  format 
(hard-copy  or  soft-copy  workstation)  as  that  routinely 
used by the facility. Sixty-two percent (554 of 889) of 
DM phantom images were scored on a computer monitor. 
If  the  soft-copy  image  score  failed  to  meet  minimum 
standards,  a  hard-copy  image  was  evaluated  prior  to 
issuing  a  citation  to  the  facility.  Table  2  summarises 
image  quality  scores  for  the  three  individual  object 
groups  (without  artefact  subtraction),  and  the  total  net 
score,  including  artefact  subtraction.  Average  image 
quality score (net score including artefact subtraction) for 
DM (13.5 objects) was significantly higher (p < 0.001) 
than for SF (12.3 objects). If the presence of artefacts is 
not accounted for, the difference between the mean raw 
total score for SF (12.8 objects) and DM (13.6 objects) 
decreased  (Figure  11),  but  was  still  statistically 
significant (p < 0.001). Most of the contribution to higher 
total raw scores for DM was from the mass object group 
(p  <  0.001),  while  the  smallest  yet  also  statistically 
significant (p < 0.001) difference was observed for the 
speck object group. 
Analysis  of  raw  object  scores  can  indicate  the 
overall  ability  of  the  system  to  visualize  clinically 
relevant  features,  whereas  the  presence  of  image 
artefacts is an indicator of the tendency of the system to 
superimpose  false  structures  on  the  clinical  image. 
Seventy-three  percent  (6,270  of  8,568)  of  phantom 
images  produced  using  SF  technology  were  found  to 
have at least one artefact compared to 30 percent (267 of 
892) of phantom images produced using DM. For both 
modalities,  the  artefact  type  that  was  identified  most 
frequently by the inspector was a speck-like artefact, and 
occurred in 25% (222 of 892) of DM images and 71% 
(6,102 of 8,568) of SF images. The least frequent artefact 
type was a mass-like artefact, identified on only 2% (17 
of  892)  of  DM  images  and  4%  (306  of  8,568)  of  SF 
images. Specifically for DM, there was a slightly higher 
occurrence of artefacts for soft-copy review than for the 
hard-copy  format  across  all  object  groups,  and  overall 
artefacts were observed on 24% (82 of 335) of hard-copy 
films  and  on  33%  (183  of  554)  of  soft-copy  images. 
Possible  reasons  for  the  much  lower  incidence  of 
artefacts  with  DM  compared  to  SF  may  include  the 
elimination of conventional film processing and related 
artefacts  associated  with  SF,  and  any  software-based 
image processing features or other electronic features in 
DM  such  as  flat-field  corrections  that  may  reduce  the 
presence or visualisation of artefacts. 
Is better image quality associated with higher dose? 
In screen-film imaging, reducing dose can result in lower 
image  quality  scores  depending  on  the  sensitometric 
properties  of  the  film.  In  DM,  the  pixel-based  signal-
noise ratio can be reduced. For both SF and DM, linear 
regression analysis for a dependence of phantom image 
quality  score  (without  artefact  subtraction)  on  dose 
yielded only a weak relationship (correlation coefficient 
(r) < < 1). However, the null hypothesis- that the slope of 
the regression line is zero- was rejected (p < 0.001) for 
both imaging modalities. Testing was also performed for 
a  possible  difference  in  image  quality  between 
mammography units that produced doses below 1.0 mGy 
compared with mammography units having doses greater 
than 2.0 mGy. These ranges were selected because they 
exclude the average dose values that have occurred for 
the populations of inspected facilities between 1995 and 
2006. For SF mammography, the average raw total score 
for  doses  below  1.0  mGy  was  12.3  objects  compared 
with 13.0 objects for doses greater than 2.0 mGy. For 
DM,  the  corresponding  average  image  quality  scores 
were 13.1 and 13.8 objects, respectively, for doses below 
1.0 mGy and above 2.0 mGy. The difference in average 
raw total score for the  two  dose groups is statistically 
significant  (p  <  0.001)  for  both  SF  and  DM.  These 
findings, which characterize aspects of the dose-phantom 
image  quality  relationship  for  a  population  that  is 
representative of the state of practice, demonstrate that 
dose has a weak but observable impact on image quality 
(Figure  12).  Haus  et  al.  [15]  observed  a  similar 
relationship in which phantom image score failure rates 
were  significantly  higher  for  doses  below  1.0  mGy 
compared with doses in the range of 1.5-2.0 mGy. 
DISCUSSION AND CONCLUSIONS 
The  annual  number  of  screening  mammography 
exams  conducted  in  the  U.S.  has  steadily  increased 
between  1997  and  2006,  with  hospitals  and  private 
practice sites conducting the majority of exams. DM is 
allowing facilities to increase their exam workloads, and 
such facilities are estimated to conduct almost a quarter 
of all mammography exams.  
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Figure 8  Distributions of facility types for mammography facilities using only screen-film technology (left) and 
for facilities that had at least one digital mammography unit (right). Data for screen-film is for January 
to October, 2006. Data for digital mammography is from August 2005 to October 2006. 
 
 
 
 
 
 
Figure 9  Annual screening exam workload per facility for sites that used only screen-film technology and for 
sites that had at least one digital mammography unit. Box bottom and top borders are 25
th and 75
th 
percentiles respectively, and box contents are 50
th percentile (line) and mean value (diamond). Whiskers 
indicate 5
th and 95
th percentiles. 
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Figure 10 Mean glandular dose for screen-film versus digital mammography units. For both modalities dose was 
captured from the facility’s medical physics survey report. Box bottom and top borders are 25
th and 75
th 
percentiles respectively, and box contents are 50
th percentile (line) and mean value (diamond). Whiskers 
indicate 5
th and 95
th percentiles. 
 
 
 
 
Figure 11 Phantom image-quality score for screen-film versus digital mammography units. Total score without 
artifact subtraction is reported. Box bottom and top borders are 25
th and 75
th percentiles respectively, 
and box contents are 50
th percentile (line) and mean value (diamond). Whiskers indicate 5
th and 95
th 
percentiles. 
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Figure 12 Scatter plots and linear fits of mean phantom image score (without artifact subtraction) versus mean 
glandular dose. Note that phantom scores are constrained to integer and half-integer values. 
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Figure 13 Dose and image quality trends for mammography in the United States. Data were obtained from the 
following sources. 
  1974  (dose):  Bicehouse  HJ.    Survey  of  Mammographic  Exposure  Levels  and  Techniques  Used  in 
Eastern Pennsylvania. 7th Annual National Conference on Radiation Control,  1975. DHEW Publication 
(FDA) 76-8026. 
  1976 (dose): Butler PF, Jensen JE.  Breast Exposure: Nationwide Trends; A Mammographic Quality 
Assurance Program- Results to Date.  Radiologic Technology 50(3), 1978; pp 251-257. 
  1980 (dose): Breast Exposure: Nationwide Trends. In: Internal project progress report. Rockville MD: 
Bureau  of  Radiological  Health,  US  Department  of  Health  and  Human  Services,  Food  and  Drug 
Administration, 1981. 
  1985, 1988, 1992 (dose and image quality): Conway BJ, Suleiman OH, Rueter FG, Antonsen RG, 
Slayton RJ. National Survey of Mammographic Facilities in 1985, 1988, and 1992. Radiology 1994; 
191: 323-330. 
  1995-2006  (dose  and  image  quality):    Mammography  Quality  Standards  Act  (MQSA)  inspection 
findings.  
  Image Quality scores are reported for following phantoms: 
1985: RMI 152 phantom with 'C' insert 
1988: RMI 156 phantom with 'C' insert 
1992 to present: RMI 156 phantom with 'D' insert (or equivalent) 
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Table 1  MQSA inspection results for selected technical parameters: January to December, 1995. 
Unless otherwise indicated, 
tabulated values are:       
N / Mean / SD 
Hospitals  Private 
Practice 
Breast 
Clinics 
Other 
facilities  ALL 
Mean Glandular Dose
a (mGy)  5715/1.50/0.42  4959/1.51/0.42  730/1.47/0.39  293/1.58/0.44  11697/1.51/0.42 
kVp  5732/25.9/1.2  4977/26.0/1.4  734/25.9/1.0  293/25.9/1.1  11736/26.0/1.2 
HVL (mm Al)  5732/0.32/0.03  4977/0.33/0.05  734/0.33/0.02  293/0.32/0.02  11736/0.33/0.04 
Phantom Image  
Background OD  5732/1.43/0.22  4977/1.42/0.23  734/1.44/0.21  293/1.41/0.23  11736/1.42/0.23 
Fibers
b  5729/4.6/0.6  4923/4.5/0.6  731/4.6/0.6  293/4.5/0.7  11676/4.5/0.6 
Specks
b  5729/3.7/0.5  4923/3.7/0.5  731/3.7/0.5  293/3.7/0.6  11676/3.7/0.5 
Masses
b  5729/3.6/0.6  4923/3.6/0.6  731/3.7/0.5  293/3.6/0.6  11676/3.6/0.6 
Total Net Score
c  5705/11.5/1.1  4955/11.4/1.1  732/11.6/1.0  290/11.4/1.1  11682/11.5/1.1 
Film Processing: 
% < 80
d 
4.5  
(80/1777) 
3.4  
(60/1742) 
1.8  
(2/109) 
8.0  
(7/88) 
4.0  
(149/3717) 
Darkroom Fog: 
% > 0.05 OD
e 
10.5  
(352/3365) 
12.1  
(381/3156) 
8.8  
(29/328) 
8.8  
(16/181) 
11.1  
(778/7030) 
% Phantom Images  
with artifacts 
62.2  
(3565/5729) 
57.1 
(2812/4923) 
56.9  
(416/731) 
63.5  
(186/293) 
59.8  
(6979/11676) 
aDose was calculated from data acquired by the MQSA inspector. 
bObject score is reported without artifact subtraction. 
cScore includes artifact subtraction. 
dPercentage of standard-cycle film processors with a speed less than 80, as determined by the STEP method. 
ePercentage of facilities found to have darkroom fog greater than 0.05 net optical density. 
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Screen-film  based  mammography  in  the  U.S.  has 
matured  technically  as  both  imaging  equipment 
performance  and  facility  clinical  practices  have 
promoted reduced variability in MGD and indicators of 
image  quality.  Figure  13  shows  the  trends  in 
mammography  dose  and  image  quality  in  the  U.S. 
between the mid-1970s and 2006, and it highlights two 
aspects  of  the  clinical  practice.  Prior  to  the  1990s, 
changes  in  the  technical  aspects  of  mammography 
dramatically reduced radiation dose (risk) and improved 
image  quality  (clinical  benefit).  As  mammography 
technology  matured  and  mandatory  quality  standards 
were  instituted  nationally,  dose  actually  increased 
slightly as the professional community optimised image 
quality to a stable level. 
Average MGD in the U.S. currently is higher than 
those  reported  in  surveys  conducted  in  several  other 
countries. Young et al. reported for the UK in 2001 and 
2002 an average MGD of 1.42 mGy for a slightly larger 
compressed  breast  thickness  of  45  mm  in  their  model 
[17].  They  also  reported  a  similar  increasing  trend  in 
dose in the breast model compared to a previous survey 
conducted there in 1997 to 1998. A survey conducted in 
the  Netherlands  also  reported  lower  doses;  however 
breast  doses  were  based  on  tissue  glandularity  and  an 
average compression thickness between 5.4 cm (average 
MGD of 1.04 mGy) and 6.2 cm (average MGD of 1.63 
mGy) depending on locality [18]. Jamal et al. reported an 
average  MGD  from  a  survey  in  Malaysia  conducted 
between  1999  and  2001  of  1.23  mGy  using  the  RMI 
model  156  phantom  [19]  and  reported  an  average 
phantom image background optical density (1.28) well 
below  the  value  reported  in this  paper  for  the  U.S.  in 
2006.  Image  quality  indicators  should  be  considered 
before  concluding  that  there  is  a  clinical  benefit  to 
administering lower doses. 
Film processing quality in the U.S. has continued to 
improve and standard cycle processing has become the 
de facto standard in mammography. In 1995, over 25% 
(957 of 3,717) of tested (standard cycle) film processors 
were operating at a speed below 90 compared with only 
1.3%  (73  of  5,861)  of  film  processors  tested  in  2006. 
This  observation  and  the  fact  that  dose  has  actually 
increased  on  average  both  indicate  that  facilities  have 
increasingly  directed  their  efforts  toward  improving 
clinical benefit. 
Although  screen-film  based  mammography  is  still 
the dominant imaging format, data reported in this paper 
suggest  that  DM  can  offer  at  least  comparable  and 
possibly superior image quality performance with lower 
mammographic  dose.  This  study  did  not  evaluate 
additional  features  provided  by  digital-based  imaging 
such  as  computer-assisted  manipulation  of  the  image. 
Although  these  findings  suggest  that  DM  is  currently 
producing  better  image  quality  as  indicated  by  higher 
scores  for  test  objects  including  significantly  fewer 
artefacts, it remains to be shown that they are clinically 
significant. The results of the ACRIN DMIST trial [20] 
indicating that DM is not superior to SF imaging for all 
patients is consistent with the conclusion that DM at this 
time is still a maturing technology not yet definitively 
superior to screen-film mammography. 
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